There are 702 resources available
389P - Serum MUC5AC predicts recurrence in pancreatic ductal adenocarcinoma patients on neoadjuvant chemotherapy before resection
Presenter: Ravi Kumar Paluri
Session: Poster Display session
390P - OriA362: A promising CLDN18.2/4-1BB bispecific antibody for targeting pancreatic and gastric cancers with high efficacy and safety profile
Presenter: Xiaowen He
Session: Poster Display session
391P - Phase II results of the porcupine (PORCN) inhibitor zamaporvint (RXC004) in patients with pancreatic and biliary tract cancer
Presenter: John Bridgewater
Session: Poster Display session
392P - Onset of symptoms prior to diagnosis of pancreatic and biliary tract cancer: Identification of areas of unmet needs for early diagnosis
Presenter: Andrea Martirena
Session: Poster Display session
393P - Integrating deep learning-based dose distribution prediction with Bayesian networks for decision support in respiratory motion controlled radiotherapy
Presenter: DONG-YUN KIM
Session: Poster Display session
398P - Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Additional analysies from 45-month (mo) follow-up of CheckMate 648
Presenter: Antoine Adenis
Session: Poster Display session
399P - A Quality-adjusted Time Without Symptoms and Toxicity (Q-TWiST) analysis comparing nivolumab plus chemotherapy (N+CT) or nivolumab plus ipilimumab (N+I) vs CT in patients (pts) with tumor cell PD-L1 = 1% advanced esophageal squamous cell carcinoma (ESCC):
Presenter: Ian Chau
Session: Poster Display session
400P - Comparison of pathologic response to neoadjuvant chemoradiotherapy with oxaliplatin/capecitabine and carboplatin/paclitaxel regimens in esophageal cancer: A randomized phase II trial
Presenter: Borna Farazmand
Session: Poster Display session
401P - Vibostolimab coformulated with pembrolizumab (vibo/pembro) + chemotherapy (chemo) as first-line treatment for advanced esophageal cancer (ec): Results from cohort E of the phase II KEYVIBE-005 study
Presenter: Chih-Hung Hsu
Session: Poster Display session